Regulation of Peripheral Blood Count by Benralizumab
Treatment with benralizumab in CSU decreased eos% significantly. The averages (min., max.) of eos% at baseline, post-placebo visit, and 4-weeks after the third benralizumab dose were 3.8 (0, 10), 3 (0.2, 6.3), and 0 (0, 0.2), respectively. Significant differences were observed immediately after the first dose of benralizumab (visit 3) compared to baseline (visit 1) (mean difference=3.7, p=0.0002) (Table 2 & S-Figure 1 ). These differences persisted 8-weeks after the last benralizumab dose (Visit 6) and were seen for responders as well as non-responders.